Swedish Orphan Biovitrum AB (publ) (LON:0MTD)

Market Cap	7.46B
Revenue (ttm)	1.88B
Net Income (ttm)	280.39M
Shares Out	n/a
EPS (ttm)	0.81
PE Ratio	26.59
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,830
Average Volume	32,623
Open	261.70
Previous Close	262.00
Day's Range	260.20 - 263.00
52-Week Range	17.57 - 25.61
Beta	0.30
RSI	50.86
Earnings Date	Mar 31, 2025

About LON:0MTD

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology and Specialty Care. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for hae...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1939
• Employees: 1,806
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0MTD

Financial Performance

In 2024, LON:0MTD's revenue was 26.03 billion, an increase of 17.65% compared to the previous year's 22.12 billion. Earnings were 3.89 billion, an increase of 61.27%.

Financial numbers in SEK